Close Menu

NEW YORK – UK-based gene synthesis firm Evonetix announced Monday it has closed a £23million ($29.4 million) Series B financing round.

New investor Foresite Capital led the round, joined by existing investors Draper Esprit, DCVC, the Morningside Group, Providence Investment Company, Cambridge Consultants, Rising Tide Fund, and Civilization Ventures. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.